150 related articles for article (PubMed ID: 38468231)
21. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer.
Maae E; Olsen DA; Steffensen KD; Jakobsen EH; Brandslund I; Sørensen FB; Jakobsen A
Breast Cancer Res Treat; 2012 May; 133(1):257-65. PubMed ID: 22270936
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
24. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
26. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP; Wang M; Radovich M; Sledge GW; Badve S; Thor A; Flockhart DA; Hancock B; Davidson N; Gralow J; Dickler M; Perez EA; Cobleigh M; Shenkier T; Edgerton S; Miller KD;
J Clin Oncol; 2008 Oct; 26(28):4672-8. PubMed ID: 18824714
[TBL] [Abstract][Full Text] [Related]
27. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance.
Escudero-Esparza A; Martin TA; Douglas-Jones A; Mansel RE; Jiang WG
Oncol Rep; 2010 Feb; 23(2):537-44. PubMed ID: 20043119
[TBL] [Abstract][Full Text] [Related]
28. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.
Goussia A; Simou N; Zagouri F; Manousou K; Lazaridis G; Gogas H; Koutras A; Sotiropoulou M; Pentheroudakis G; Bafaloukos D; Markopoulos C; Patsea H; Christodoulou C; Papakostas P; Zaramboukas T; Samantas E; Kosmidis P; Venizelos V; Karanikiotis C; Papatsibas G; Xepapadakis G; Kalogeras KT; Bamia C; Dimopoulos MA; Malamou-Mitsi V; Fountzilas G; Batistatou A
PLoS One; 2018; 13(7):e0200302. PubMed ID: 30063723
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
[TBL] [Abstract][Full Text] [Related]
30. NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer.
Zhuo YJ; Shi Y; Wu T
Oncol Lett; 2019 Nov; 18(5):4629-4638. PubMed ID: 31611971
[TBL] [Abstract][Full Text] [Related]
31. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
[TBL] [Abstract][Full Text] [Related]
32. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.
Akagi M; Kawaguchi M; Liu W; McCarty MF; Takeda A; Fan F; Stoeltzing O; Parikh AA; Jung YD; Bucana CD; Mansfield PF; Hicklin DJ; Ellis LM
Br J Cancer; 2003 Mar; 88(5):796-802. PubMed ID: 12618892
[TBL] [Abstract][Full Text] [Related]
33. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
34. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA; Schoenfeld AJ; Makhnin A; Kim R; Rizvi H; Tsui D; Falcon C; Houck-Loomis B; Meng F; Yang JL; Tobi Y; Heller G; Ahn L; Hayes SA; Young RJ; Arcila ME; Berger M; Chaft JE; Ladanyi M; Riely GJ; Kris MG
JAMA Oncol; 2020 Jul; 6(7):1048-1054. PubMed ID: 32463456
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Lebellec L; Bertucci F; Tresch-Bruneel E; Ray-Coquard I; Le Cesne A; Bompas E; Blay JY; Italiano A; Mir O; Ryckewaert T; Toiron Y; Camoin L; Goncalves A; Penel N; Le Deley MC
BMC Cancer; 2018 Oct; 18(1):963. PubMed ID: 30305054
[TBL] [Abstract][Full Text] [Related]
37. Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.
Bernatz S; Monden D; Gessler F; Radic T; Hattingen E; Senft C; Seifert V; Ronellenfitsch MW; Plate KH; Harter PN; Baumgarten P
J Mol Histol; 2021 Apr; 52(2):233-243. PubMed ID: 33528717
[TBL] [Abstract][Full Text] [Related]
38. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
[TBL] [Abstract][Full Text] [Related]
39. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
